THE EVIDENCE RECORD · VERIFIED VS. DISPUTED
PT-141 research: what the literature establishes, and what it does not
The human trials, the mechanism studies, and the disputed work — sorted, not blended.
Before the details
This page lays out the PT-141 research record in order of how solid it is. At the top sit the human trials that actually carried the drug to approval. Below them sit the mechanism studies — animal work and brain-imaging — that explain how it works. At the bottom sit the disputed and early-development reports that the marketing tends to quote as if they were settled.
The reason for the order is simple. PT-141 (bremelanotide) is approved for one thing, in one population, on the strength of two large trials [3]. Everything else is weaker evidence, and treating it all as equally strong is how hype gets made. We keep the established findings and the disputed ones visibly apart — each major finding gets its own heading, and every quantitative claim is cited.
The Phase 3 human trials (established)
The pivotal evidence is the RECONNECT program: two identical Phase 3 randomized controlled trials enrolling 1,267 premenopausal women with HSDD [3]. Pharmacology reviews position it as an approved but limited-efficacy option for premenopausal HSDD, urging that risks and benefits be weighed [15]. A 1.75 mg as-needed subcutaneous dose met both coprimary endpoints — improved sexual desire (integrated FSFI-desire +0.35, P<.001) and reduced desire-related distress (integrated FSDS-DAO item 13 −0.33, P<.001) versus placebo over 24 weeks [3]. The most common adverse events were nausea, flushing, and headache [3].
Durability was tested in a 52-week open-label extension of 684 women: efficacy was sustained, no new safety signals appeared, and the most common drug-related events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. This is the firmest part of the whole record.
The mechanism evidence (established)
Several lines of work establish that PT-141 acts centrally. A placebo-controlled, double-blind crossover fMRI study of 31 premenopausal women with HSDD found that MC4R agonism increased sexual desire for up to 24 hours and altered brain processing of erotic stimuli — enhancing amygdala-insula connectivity and cerebellar/supplementary-motor activity [5]. In female rats, the drug selectively boosted desire-driven (appetitive) sexual behavior without affecting reflexes, pacing, or movement [2].
The peripheral-versus-central question was tested directly. In rabbit vaginal-wall and arterial tissue, the natural peptide alpha-MSH relaxed the tissue but bremelanotide (1 µM) did not — consistent with a central, not a local vascular, mechanism [8]. High-resolution structures of the full-length MC4R bound to bremelanotide further resolve exactly how the peptide engages the receptor [12]. Early reviews describe rapid, dose-dependent erectile activity in men via this same central route [1][9].
The disputed and limited evidence (be skeptical)
This is where due diligence matters most. A 2008 erectile-dysfunction salvage study by Safarinejad and Hosseini received a formal Expression of Concern in 2023, meaning its integrity is in question; its findings should be treated as disputed. Independent re-analyses argue the approved-indication trial effects on desire and distress, while statistically significant, are small, and they question the clinical meaningfulness of the outcome measures [3].
A 2025 hamster study adds a nuanced, partly negative note: neither low nor high doses changed melanocortin-receptor expression in the mesolimbic dopamine system, and the drug did not enhance sexual reward in a conditioned place-preference test — suggesting it does not act on the brain's reward (VTA-NAc) circuit [6]. And for male erectile dysfunction broadly, a 2025 narrative review classes PT-141 as investigational, with large trials still needed to establish safety and dosing [11]. The honest summary: a narrow, well-supported approval surrounded by a much larger zone of thin or contested evidence.